Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Antagonistas opiáceos con sedación mínima para la abstinencia de opiáceos

Información

DOI:
https://doi.org/10.1002/14651858.CD002021.pub4Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 29 mayo 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Alcohol y drogas

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Linda Gowing

    Correspondencia a: Discipline of Pharmacology, University of Adelaide, Adelaide, Australia

    [email protected]

  • Robert Ali

    Discipline of Pharmacology, University of Adelaide, Adelaide, Australia

  • Jason M White

    School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

Contributions of authors

Linda Gowing assessed each potentially relevant study according to identified inclusion and exclusion criteria, extracted key information and compiled a first draft of the review. Robert Ali and Jason White confirmed and commented on review content.

Sources of support

Internal sources

  • Drug and Alcohol Services South Australia, Australia.

External sources

  • Commonwealth Department of Health and Aging, Australia.

Declarations of interest

Linda Gowing: none known.

Robert Ali: none known.

Jason White: none known.

Acknowledgements

Dr Zhao Chengzheng and Dr Liang Jianhui translated and assisted with assessment of a study considered for this review (He 1999) that was published in Chinese.

Version history

Published

Title

Stage

Authors

Version

2017 May 29

Opioid antagonists with minimal sedation for opioid withdrawal

Review

Linda Gowing, Robert Ali, Jason M White

https://doi.org/10.1002/14651858.CD002021.pub4

2009 Oct 07

Opioid antagonists with minimal sedation for opioid withdrawal

Review

Linda Gowing, Robert Ali, Jason M White

https://doi.org/10.1002/14651858.CD002021.pub3

2009 Jul 08

Opioid antagonists with minimal sedation for opioid withdrawal

Review

Linda Gowing, Robert Ali, Jason M White

https://doi.org/10.1002/14651858.CD002021.pub2

2002 Apr 22

Opioid antagonists with minimal sedation for opioid withdrawal

Review

Linda Gowing, Robert Ali, Jason M White

https://doi.org/10.1002/14651858.CD002021

Notes

The first version of this review was entitled 'Opioid antagonists and adrenergic agonists for the management of opioid withdrawal'.

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Flow diagram of literature search
Figuras y tablas -
Figure 1

Flow diagram of literature search

Ir a la figura de la revisiónAbrir en una pestaña nueva

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Figuras y tablas -
Figure 2

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figuras y tablas -
Figure 3

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 1 Peak withdrawal severity.
Figuras y tablas -
Analysis 1.1

Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 1 Peak withdrawal severity.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 2 Overall withdrawal severity.
Figuras y tablas -
Analysis 1.2

Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 2 Overall withdrawal severity.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 3 Completion rate.
Figuras y tablas -
Analysis 1.3

Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 3 Completion rate.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Summary of findings for the main comparison. Antagonist‐adrenergic combination compared to adrenergic agonist for opioid withdrawal

Antagonist‐adrenergic combination compared to adrenergic agonist for opioid withdrawal

Patient or population: opioid dependent adults
Setting: inpatient or outpatient
Intervention: antagonist‐adrenergic combination
Comparison: adrenergic agonist

Outcomes

Impact

№ of participants
(studies)

Quality of the evidence
(GRADE)

Peak withdrawal severity ‐ Naltrexone

In 1 study peak withdrawal severity was similar for the 2 types of intervention. In the other study peak withdrawal was more severe in the group receiving antagonist‐adrenergic combination.

184
(2 RCTs)

⊕⊝⊝⊝
Very lowa,b,c

Peak withdrawal severity ‐ Naloxone

This comparison reported by only 1 study, which found more severe withdrawal with naloxone‐clonidine combination.

91
(1 RCT)

⊕⊝⊝⊝
Very lowa,c

Overall withdrawal severity ‐ Naltrexone

No difference in overall withdrawal severity for 2 studies; in 1 study overall severity significantly less for antagonist‐adrenergic combination.

256
(3 observational studies)

⊕⊝⊝⊝
Very lowb,c,d

Overall withdrawal severity ‐ Naloxone

This comparison reported by only 1 study, which found less severe overall withdrawal with naloxone‐lofexidine combination.

49
(1 observational study)

⊕⊝⊝⊝
Very lowa c

Completion rate ‐ Naltrexone

Completion rate with adrenergic agonist only ranged from 42% to 94%. Completion rate with antagonist‐adrenergic agonist combination ranged from 73% to 95%

330
(4 RCTs)

⊕⊝⊝⊝
Very lowb,c,d,e

Completion rate ‐ Naloxone

Completion rate with adrenergic agonist only ranged from 28% to 94%. Completion rate with antagonist‐adrenergic agonist combination ranged from 73% to 98%

463
(6 RCTs)

⊕⊝⊝⊝
Very lowb,c,e,f

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; OR: odds ratio

GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

aOne study at high risk of bias.
bUnexplained inconsistency in results.
cSmall studies.
dTwo studies not randomised.
eStudies at high risk of bias.
fOne study not randomised.

Figuras y tablas -
Summary of findings for the main comparison. Antagonist‐adrenergic combination compared to adrenergic agonist for opioid withdrawal
Ir a la tabla de la revisión
Comparison 1. Antagonist‐adrenergic combination versus adrenergic agonist

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Peak withdrawal severity Show forest plot

2

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

1.1 Naltrexone

2

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

1.2 Naloxone

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

2 Overall withdrawal severity Show forest plot

4

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

2.1 Naltrexone

3

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

2.2 Naloxone

1

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

3 Completion rate Show forest plot

9

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

3.1 Naltrexone

4

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

3.2 Naloxone

6

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 1. Antagonist‐adrenergic combination versus adrenergic agonist
Ir a la tabla de la revisión